Compositions for eliminating bacterial promotors of colorectal cancer by intraluminal application
Topical administration of fosfomycin directly into the intestinal lumen targets Fusobacteria and biofilms in colorectal cancer, addressing tumor growth and resistance, and enhancing treatment efficacy by reducing systemic side effects.
Patent Information
- Application Number
- JP2024166245
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-14
- Filing Date
- 2024-09-25
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Colorectal cancer (CRC) tumors are colonized by Fusobacteria and associated bacterial biofilms, which enhance tumor growth, resistance to chemotherapy and radiotherapy, and promote a pro-carcinogenic environment, necessitating targeted antimicrobial agents that minimize systemic side effects.
A topical composition containing fosfomycin, optionally with additional antibiotics like metronidazole or carbapenems, is administered directly into the intestinal lumen to target and eliminate Fusobacteria and biofilms, ensuring high antibiotic concentrations at the tumor site while minimizing systemic absorption.
This approach effectively reduces tumor growth, restores sensitivity to chemotherapy and radiotherapy, and disrupts the pro-carcinogenic effects of biofilms, thereby inhibiting tumor recurrence and enhancing treatment efficacy.
Smart Images

Figure 2024169669000001 
Figure 2024169669000002 
Figure 2024169669000003
Abstract
Description
[Technical field]
[0001] The present invention provides a composition comprising fosfomycin for topical application that eliminates or reduces colonization or infection of colorectal cancer (CRC) tumors by Fusobacteria and other susceptible microorganisms, and the presence of bacterial biofilms associated with such tumors or their development. The objective of the present invention is to reduce tumor growth and resistance to chemotherapy or radiotherapy associated with the infection, and to reduce the pro-carcinogenic effects attributable to biofilms. The present invention relates to the fields of oncology and gastroenterology, as well as other fields including the prevention and treatment of colorectal cancer. [Background technology]
[0002] The term "Fusobacteria" refers to members of the genus Fusobacterium, a gram-negative anaerobic bacterium whose species, including F. nucleatum, are found in the oral cavity and are involved in periodontal disease. Fusobacterial genomic sequences have been found to be enriched in CRC tumors, with prominent DNA sequences related to F. nucleatum (Kostic et al. 2012). Excess F. nucleatum RNA has also been detected in such tumors (Castellarin et al. 2012).
[0003] Fusobacteria target colorectal adenocarcinoma cells, and certain other adenocarcinomas, with their Fap2 lectin, which specifically binds to D-galactose-β(1-3)-N-acetyl-D-galactosamine (Gal-GalNAc) residues on colorectal surface carbohydrates. Once inside tumors, Fusobacteria can enhance cell proliferation (Rubinstein et al. 2013; Chen et al. 2017; Yang et al. 2017), create a favorable inflammatory environment for tumors (Kostic et al. 2013), and protect cancer cells from killing by natural killer cells and tumor-infiltrating T cells. F. nucleatum also promotes resistance of CRC to chemotherapy (Yu et al. 2017) and to radiotherapy by involving similar cellular mechanisms. High Fusobacteria abundance in CRC correlates with poor disease outcome (Flanagan et al. 2014). At the same time, there is a need for antibacterial agents that specifically target Fusobacteria so as to avoid the side effects of systemically administered broad-spectrum antibiotics.
[0004] Fusobacteria such as F. nucleatum are also present in bacterial biofilms associated with CRC tumors, especially those of the ascending colon. In these biofilms, bacteria from the genera Bacteroides and Prevotella are often most prominent, along with Enterobacteriaceae such as Escherichia coli, but bacilli including Clostridium spp., actinomycetes, and various putatively protective lactobacilli can also be found in addition to fusobacteria. Biofilms associated with CRC tumors are characteristically thick and continuous, invading deeper mucus layers and contacting colonic epithelial cells to reside on the tumor and on adjacent normal epithelium. Tissues underlying the biofilm show reduced or altered expression of the tumor suppressor E-cadherin, enhanced expression of the proinflammatory and angiogenic cytokines IL-6 and proliferation-associated Ki-67 protein, and Stat3 activation. This points to a pro-carcinogenic effect of biofilms (Dejea et al., 2016). Among the specific ways in which bacteria present in biofilms may initiate CRC are direct mutagenic effects on DNA or interference with host DNA repair. This is the case for enterotoxigenic Bacteroides fragilis (ETBF), superoxide-producing Enterococcus faecalis, and colibactin-producing E. coli. Many of the biofilm bacteria can enhance the Wnt-mediated signaling pathway or other specific pro-inflammatory pathways that are commonly mutated and / or overexpressed in CRC, as seen in the abovementioned bacterial strains and in F. nucleatum. There are also local immunological effects of biofilms, as shown by the promotion of tumorigenic Th17 responses by ETBF, demonstrated in a mouse model (Chung et al., 2018). These mechanisms that promote the initiation of CRC also tend to be involved in CRC progression as well (Drewes et al. 2016).Colon biofilms and CRC tumors, especially those of the ascending colon, appear to enter into a symbiotic relationship whereby each component may promote the formation and growth of the other part of a vicious cycle.Some of these factors originate from both biofilms and tumors, N. 1 ,N 12 -diacetylspermine production is increased (Johnson et al. 2015). Without wishing to be bound by any theory, the inventors believe that the technical effect of local administration of fosfomycin is due to the removal of pro-tumor biofilms from the colonic mucosa, which breaks the vicious cycle, reduces CRC tumor size, helps restore sensitivity to chemotherapy and radiotherapy, and tends to normalize the immune response against the tumor, thereby reducing the initiation of recurrent tumors. Summary of the Invention
[0005] The present invention therefore seeks to target Fusobacterial infection or colonization of colorectal tumours and eliminate CRC-associated bacterial biofilms by providing a pharmaceutical composition for treating these conditions by local administration of the pharmaceutical composition into the lumen of the intestine where the tumour and / or biofilm is located, said composition essentially comprising:
[0006] A composition for topical administration within the intestinal lumen, comprising the antibiotic fosfomycin as an active ingredient for reducing or eliminating infection or colonization of colorectal cancer tumors by Fusobacteria and bacterial biofilms associated with such tumors.
[0007] A composition for use according to the above paragraphs further comprising one or more additional antibacterial or antibiotic agents as active ingredients.
[0008] A composition for use according to the preceding paragraphs, wherein the one or more additional antibacterial or antibiotic agents are selected from the non-limiting list including metronidazole or a carbapenem, such as ertapenem or meropenem or imipenem.
[0009] A composition for use according to the preceding paragraphs, wherein the active ingredient fosfomycin is in the form of fosfomycin trometamol or fosfomycin disodium.
[0010] A composition for use according to the preceding paragraphs, wherein the active ingredient is formulated as a dry powder or granulate which is dissolved in an aqueous medium prior to delivery into the intestinal lumen.
[0011] The composition according to the previous item, wherein the dry powder or granules and / or the aqueous medium for dissolution contain one or more additional substances that promote the penetration of the active ingredient into tumors and biofilms, said additional substances being selected from the list of dimethyl sulfoxide, glycofurol, polyoxyethylene lauryl ether, sodium taurocholate, and sodium caprate. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] In the following detailed description of the invention, details of the scope of the invention and its substantial performance are set forth below.
[0013] The objective of the present invention is to provide a means to reduce or eliminate colonization or infection of colorectal cancer tumors by Fusobacteria, as well as to eliminate the bacterial biofilms associated with these tumors. This objective is achieved by local administration of a solution of an appropriate antibiotic directly into the intestinal lumen, at a level that ensures application of the solution to the site of the tumor and / or biofilm. Tumor colonization by Fusobacteria has been associated with increased tumor growth and resistance to both endogenous antitumor immune mechanisms and exogenous antitumor therapies. Some of the mechanisms by which these effects are exerted have been elucidated. It is therefore proposed that the elimination or dramatic reduction of Fusobacterial colonization of these tumors will reverse these adverse events and increase the efficacy of other anticancer therapies targeted at these tumors. Eliminating the bacterial biofilms associated with these tumors (i.e., covering the tumor and adjacent areas of normal colonic epithelium) will also exert these effects, while also eliminating the pro-carcinogenic effects of the biofilms that may promote tumor recurrence and tumor growth.
[0014] Local administration of antibiotics via the intestinal lumen, for example by application via an endoscope or catheter, or possibly as a retention enema, will result in very high antibiotic concentrations at the luminal surfaces of tumors and biofilms. The antibiotic will penetrate into tumor cells where Fusobacteria are located, enter overlying and adjacent biofilms and reach bactericidal concentrations, while at the same time only minimally being absorbed into the blood, thus substantially reducing any systemic side effects of the antibiotic.
[0015] Quantitative polymerase chain reaction analysis of F. nucleatum DNA in tumors demonstrates that bacteria are enriched in the superficial luminal portion of tumors (Yamamura et al. 2017). Antimicrobial treatment by applying high concentrations of antibiotics from the luminal side should be particularly effective in eliminating most of the bacterial burden while minimizing side effects associated with conventional systemic administration of broad-spectrum antibiotics. The same considerations apply to the elimination of overlapping and adjacent bacterial biofilms.
[0016] Active ingredients of the compositions of the present invention The composition according to the invention essentially comprises the antibiotic fosfomycin, alone or in combination with one or more additional antibiotics which may be selected from the non-limiting list including metronidazole and carbapenems, such as ertapenem, meropenem, and imipenem.
[0017] Fosfomycin Fosfomycin, also known as fosfomycin or fosfonomycin, is the international nonproprietary name of a broad-spectrum antibiotic isolated and characterized in 1969 from a strain of Streptomyces fradiae (Hendlinra et al. 1969). Its structure was determined to be (-)(IR, 2S)-1,2-epoxypropylphosphonic acid (Christensen et al. 1969), with the organizational (IUPAC) name [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid and a formula weight of 138.1 Da. Fosfomycin is bactericidal and inhibits bacterial cell wall biosynthesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase, also known as MurA (Brown et al. 1995). This enzyme catalyzes a step involved in peptidoglycan biosynthesis, ligating phosphoenolpyruvate to the 3'-hydroxyl group of UDP-N-acetylglucosamine to form N-acetylmuramic acid. Fosfomycin is a phosphoenolpyruvate analogue that inhibits MurA by alkylating the active site cysteine residue. The antibiotic enters the bacterial cell via the glycerophosphate transporter.
[0018] Given this mechanism of action, fosfomycin has a broad bacterial spectrum, making it active against aerobic genera such as Staphylococcus, Streptococcus, Enterococcus, Neisseria, Escherichia, Proteus (indole negative), Serratia, Salmonella, Shigella, Pseudomonas, Haemophilus, and Vibrio, and less active against indole positive Proteus species, Klebsiella, and Enterobacter species. Of particular relevance to the present invention are active against anaerobic Fusobacterium and anaerobic Peptostreptococcus (Peptoniphilus, Finegoldia, and Anaerococcus), but are inactive against the anaerobic Bacteroides fragilis group of bacteria.
[0019] Within the community, the prevalence of bacterial resistance to fosfomycin is low, and studies on the prevalence of resistant bacteria after the introduction of fosfomycin show no or only a slight increase in the prevalence of resistant organisms. However, prolonged exposure to the antibiotic allows bacteria to generate resistance by selection of mutants defective in the glycerophosphate transporter pathway. Alternative mechanisms of resistance include loss of an inducible hexose phosphate transporter, Cys-Asp mutations in MurA, or acquisition of plasmids encoding the fosfomycin-inactivating enzymes fosA and fosB (in addition to chromosomal fosX in Listeria monocytogenes). However, mutant strains also show reduced virulence (Karageorgopoulos et al. 2012). This could explain why the emergence of bacterial resistance is seen with prolonged exposure in vitro but much less frequently in vivo. The incidence of resistant bacterial strains in controlled clinical trials of orally or intravenously administered fosfomycin was 3.0% overall and up to 15% for Pseudomonas aeruginosa. In general, fosfomycin proves to be a valuable addition to the therapeutic armamentarium against multidrug-resistant organisms.
[0020] Fosfomycin has been shown to have the ability to favor phagocytosis and act as an immunomodulator: it accumulates by polymorphonuclear leukocytes to concentrations up to twice those in the extracellular fluid that do not affect their cellular functions, yet still exerts a bactericidal effect against Staphylococcus aureus (Hoger et al. 1985).
[0021] Regarding its uptake into intestinal mucosal cells, Martinez et al. (2013) demonstrated rapid uptake of fosfomycin into IPEC-J2 cells exposed to fosfomycin calcium at 580 μg / mL, reaching an intracellular concentration close to 30 μg / mL in 15 minutes. Such high concentrations of fosfomycin are difficult to reach by standard systemic administration routes. Thus, very high concentrations of fosfomycin are required to kill fusobacteria in colorectal cancer cells. According to the present invention, such concentrations are reached with a locally administered fosfomycin solution.
[0022] Fosfomycin is known to readily penetrate through tissue barriers and into bacterial biofilms (Refert & Smith 2014), therefore high bactericidal concentrations of fosfomycin could be obtained from direct application of a fosfomycin solution to bacterial biofilms overlying and adjacent to colorectal tumors. Fosfomycin inhibits adhesion of a variety of bacterial species to epithelial cells, including those involved in biofilm formation (Gobernado 2003). Fosfomycin can also disrupt biofilms, increasing the permeability of other antibiotics.
[0023] Important side effects of fosfomycin are gastric irritation from orally administered fosfomycin disodium, evidence of allergy in the form of a transient rash (0.3% of cases) and eosinophilia (0.2%), and transiently elevated liver enzymes (0.3% of cases) from systemically administered fosfomycin (Gobernado 2003). In general, however, fosfomycin exhibits remarkably low toxicity, and therefore it is the sodium load that is the dose limiting factor when high doses of fosfomycin disodium are given systemically.
[0024] Fosfomycin, when used in combination with many antibiotics of the penicillin, cephalosporin, aminoglycoside, macrolide, and lincosamide type, shows considerable synergy in bactericidal activity against many strains of organisms from the described susceptible genera. Early studies showed synergy for about 70-100% of the strains tested with various antibiotic combinations, and subsequent more extensive studies showed synergy rates of 36-74%. The remaining strains showed merely additive effects, and inhibitory effects were only seen with combinations of one or two individual antibiotics on individual bacterial strains (Gobernado 2003). The fact that fosfomycin shows synergy with many individual antibiotics and, in fact, stops the toxicity of many other antibiotics, including the nephrotoxicity and ototoxicity of aminoglycosides, favors the use of fosfomycin in combination with other antibiotics to provide a strong bactericidal effect during longer treatments and to compensate for any development of fosfomycin resistance.
[0025] The major forms of fosfomycin that fall within the scope of the present invention are as follows: i) Fosfomycin disodium, formula weight 182.0 Da, pH of a 5% solution 9.0-10.5. This salt is hygroscopic, highly soluble in water, highly bioavailable, but is locally irritating if not neutralized. ii) Fosfomycin calcium monohydrate, formula weight 194.1 Da, pH 8.1-9.6 for a 0.4% solution. This salt is sparingly soluble in water, not hygroscopic, does not cause significant gastric irritation when used for oral therapy, and its bioavailability for entry into the systemic circulation may be as low as 12% (Bergan 1990). iii) Fosfomycin trometamol, formula weight 259.2 Da, pH of a 5% solution 3.5-5.5. This salt is highly soluble in water and well tolerated when given orally, exhibiting a bioavailability of approximately 40%.
[0026] The name "fosfomycin" as used herein refers to an inorganic or organic salt of fosfomycin embodied in the above major forms, and the dosage of fosfomycin refers to the amount of the free acid form of fosfomycin present in the salt.
[0027] The preferred form of fosfomycin for the compositions of the present invention is fosfomycin trometamol, which exhibits long-term stability as a readily dissolving granule when stored at room temperature in a sealed sachet, however, fosfomycin disodium can also be used, which, due to its significant hygroscopicity, requires storage in a sealed vial.
[0028] Compositions according to the invention may contain fosfomycin in a single dose ranging from 400 milligrams to 4 grams.
[0029] Metronidazole This semisynthetic antibiotic, active against several anaerobic bacteria, including those of the B. fragilis group and Fusobacterium species, is well known in the art. It has been used systemically in combination with systemic fosfomycin for prophylaxis against wound infections after abdominal surgery. Intracellular penetration of metronidazole appears to be by rapid passive diffusion, such that intracellular levels approach equilibrium with extracellular levels within 15 minutes (Hand et al. 1987). Compositions according to the invention may contain metronidazole in a single dose ranging from 100 milligrams to 1 gram.
[0030] Carbapenems Carbapenems are members of the beta-lactam class of antibiotics that, like penicillins and cephalosporins, exert their bactericidal action by inhibiting bacterial cell wall synthesis through a mechanism different from that of fosfomycin. Thus, beta-lactam antibiotics, including carbapenems, characteristically exhibit synergistic bactericidal action with fosfomycin against most bacterial species against which both types of antibiotics are active. However, carbapenems exhibit a broader spectrum of activity than most penicillins and cephalosporins, and are active against anaerobic bacteria such as the B. fragilis group, Prevotella species, and Fusobacterium species. Thus, they are used in place of metronidazole to exert bactericidal action against anaerobic bacteria that are highly insensitive to fosfomycin. With regard to intracellular penetration of carbapenems, bactericidal intracellular concentrations of ertapenem in a murine macrophage cell line were achieved at extracellular concentrations as low as 15 μg / mL (Tang et al. 2012), while the ratio of cellular to extracellular concentrations of meropenem in human macrophages was consistently higher (range 3-12) at extracellular concentrations ranging from 0.125 to 1 μg / mL (Cuffini et al. 1993). The compositions according to the invention may contain ertapenem, or meropenem, or imipenem in a single dose ranging from 100 milligrams to 1 gram.
[0031] Medical Indications The main indications for using the described compositions are the presence of one or more colorectal tumors arising from the colon or rectal mucosa, and / or the presence of a bacterial biofilm covering the colon or rectal mucosa, whether associated with adenocarcinoma, adenoma, or polyp, or mucosal epithelial dysplasia. The indications will typically be diagnosed in conjunction with a colonoscopy. Treatment with the described compositions can typically be administered through an endoscope during the same session, or in a later procedure by intraluminal placement of a solution of the composition in the intestinal section where the mucosal pathology is observed. Following the initial treatment, further treatments can be performed at the discretion of the treating physician.
[0032] Therapeutic indications may be provided by detecting urinary, fecal, blood, or tissue markers of pro-tumor biofilms or driver organisms. At present, such markers can be the presence of colibactin-producing E. coli, enterotoxin-producing B. fragilis, F. nucleatum, and Porphyromonas gingivalis, as well as other microorganisms, especially those from the oral microbiota. Many markers are under investigation but have not yet demonstrated sufficiently high diagnostic sensitivity or specificity to independently diagnose either CRC or colonic biofilms, and thus currently have a screening function to select subjects for colonoscopy. Among the markers with promising diagnostic sensitivity and specificity are urinary N, which is produced in increased amounts by CRC-associated bacterial biofilms as described above. 1 ,N 12 -Diacetylspermine.
[0033] If it is known or suspected that the tumor has penetrated the intestinal wall or metastasized to lymph nodes or distant tissues, the treating physician may decide to supplement local antibiotic therapy with systemic antibiotic therapy, since viable microorganisms have been found in colorectal cancer metastases.
[0034] Due to their location, tumors and biofilms present in the rectum and sigmoid colon offer the opportunity for treatment with the composition configured as a retention enema. In certain circumstances, larger volume enemas containing the composition can be used to treat areas of the colon further away from the rectum.
[0035] The use of the described compositions may be indicated during neoadjuvant radiotherapy or chemotherapy, for example during therapy with bevacizumab and / or cytotoxic drugs.
[0036] formulation In a preferred embodiment, the composition comprises fosfomycin trometamol provided as a dry granule that is dissolved in a provided pharma- ceutically acceptable carrier, preferably an aqueous carrier or diluent. The carrier may be simply water or water containing pharma- ceutically acceptable auxiliary substances or adjuvants, including but not limited to buffers and / or tonicity agents, to ensure a neutral pH and isotonicity of the fosfomycin solution. In another embodiment, the composition comprises fosfomycin disodium, for example, fosfomycin disodium formulated for intravenous injection, provided as a lyophilized powder in a capped glass vial, which is similarly dissolved in a pharma-ceutically acceptable aqueous carrier or diluent.
[0037] In a further embodiment, the composition comprises fosfomycin trometamol and an additional antibiotic, such as metronidazole, or a carbapenem, such as ertapenem, meropenem, or imipenem, where both antibiotics are supplied as a dry powder or granules to be dissolved in an aqueous carrier.
[0038] The pH value of the solutions obtained from the formulations according to the invention may have a pH between 4 and 8, preferably between 6.5 and 7.5, most preferably between 7 and 7.5. The antibiotic powder or granules and the aqueous diluent provided individually contain buffers and / or tonicity agents to ensure neutral pH and isotonicity of the combined antibiotic solution. They may contain one or more approved biocompatible thickeners that do not bind the active ingredients of the composition, such as hydroxypropyl methylcellulose, or a large number of other biocompatible thickeners known in the art, to achieve a solution of optimal viscosity for controlled delivery and adhesion to the colonic mucosa.
[0039] The aqueous diluent may contain up to 2% by weight of an adjuvant such as dimethylsulfoxide (DMSO) and / or up to 1% by weight of glycofurol to promote the uptake of the active ingredient by the tumor. Other adjuvants performing similar functions may be used together with or in place of DMSO or glycofurol; these may be selected from the list including polyoxyethylene lauryl ether, sodium taurocholate, and sodium caprate. These adjuvants will be present in concentrations less than 1% by weight.
[0040] In some embodiments, dry preparations of compositions according to the invention may be prepackaged, for example in single dose units, or even supplied prepackaged in single dose vials, for dissolution in an aqueous diluent immediately prior to administration.
[0041] Administration The compositions of the invention may be applied by administration methods conventionally used in the art for local administration to the lumen of the intestine, at areas of mucosal CRC tumors, adenomas, or areas of mucosal dysplasia, or areas of bacterial biofilms located in the colon or rectum.
[0042] When the colon and rectum have been cleared of fecal material using standard regimens of bowel preparation for colonoscopy or surgery, such as drinking or orally administering large volumes of liquid containing polyethylene glycol in appropriate concentrations, such as macrogol 3350 or 4000, with or without electrolytes, the tumor or biofilm is located in the lower rectum or sigmoid colon, and a solution of the composition is administered as a retention enema into the intestinal lumen at the level of the tumor. In certain circumstances, the composition may be administered in larger volume enemas for treatment of conditions closer to the colon.
[0043] For tumors and biofilms located in the more proximal portions of the colon, a solution of the composition can be administered at the level of the pathology during colonoscopy.
[0044] In exceptional circumstances, when rectal or sigmoid tumors are treated when no bowel preparation has been performed, administration of a solution of the composition may be performed after first emptying the bowel by administering a laxative and then giving a colonic enema to cleanse the bowel;
[0045] For tumors in the rectum and lower sigmoid colon, retention enemas have a volume of 50 mL to 100 mL. The patient is instructed to lie on their side, forward and backward for 5 minutes on each side and to hold the enema for at least 15 minutes, if possible. If the tumor is located in a more proximal portion of the colon, a larger volume enema can be given, or a solution of the composition can be injected into the tumor area during colonoscopy as described above.
[0046] Dosage Although the present invention should guide the clinician's selection of the appropriate dosage for each individual case, it is suggested that the compositions be formulated so that the unit dose of fosfomycin in the compositions of the present invention is in the range of 400 milligrams to 4 mg. The unit dose of metronidazole or carbapenem when used as an additional antibiotic in these compositions may be in the range of 100 milligrams to 1 gram. These doses may be exceeded at the physician's discretion, for example when large volume enemas are to be given.
[0047] A typical single dose would consist, by way of example, of 1 gram of fosfomycin dissolved in 50 mL of aqueous diluent, i.e. constituting about a 2% weight / volume solution. If metronidazole or a carbapenem is required as an additional antibiotic, it may be added, for example, as 250 milligrams in the same diluent, i.e. constituting about a 0.5% weight / volume solution.
[0048] The unit doses may be increased proportionately in dosage and volume to maintain the same concentrations of fosfomycin and, if present, the additional antibiotics listed above, up to a maximum volume of 200 mL of diluent containing 4 grams of fosfomycin and 1 gram of the additional antibiotics, if present.
[0049] If a larger volume of solution is required for a single dose, the single dose described above can be prepared by diluting with isotonic saline, without increasing the amount of fosfomycin administered above 4 grams, or increasing the amount of additional antibiotic administered above 1 gram. Alternatively, the antibiotic dosage can be increased up to a maximum of 20 grams of fosfomycin in 1 liter on any one day, at the physician's discretion, while ensuring that the solution is isotonic.
[0050] Doses may be administered preferably once per day, and if the treating physician deems necessary and practicable, may be administered twice per day so that the patient receives two typical single doses per day on two separate occasions, or may even be administered three times per day so that the patient receives three typical single doses per day on three separate occasions, and exceptionally may be administered four times per day so that the patient receives four typical single doses per day on four separate occasions, may be administered five times per day, or may be administered six times per day.
[0051] The duration of the above dosing regimens will typically be short, ranging from 1 to 2 days, but if the treating physician considers that extended treatment is necessary to achieve the desired result, the dosing regimen can be extended up to 14 days, for example ranging from 3 to 5 days, such as 4 days, or ranging from 5 to 7 days, for example 6 days, or ranging from 7 to 14 days. Treatment can also be given for 1 or 2 days, followed by a break, and then repeated after 1 or 2 weeks.
[0052] Compositions according to the invention may contain fosfomycin such that a single dose is typically in the range of 400 milligrams to 4 grams dissolved in a volume of aqueous diluent in the range of 20 mL to 200 mL.
[0053] Preferably, the single dose may contain about 2% to 2.5% weight / volume of the total active ingredients in solution. Preferably, the single dose is in an isotonic solution.
[0054] In some embodiments, the compositions of the invention are intended to be administered one or several times, for example two, three, or four times, after which treatment is discontinued and resumed only as required by the attending physician.
[0055] Treatment method The present invention provides methods for reducing or eliminating colorectal infection or colonization by Fusobacteria, as well as for eliminating colonic bacterial biofilms, using local administration of the compositions of the present invention in the intestine.
[0056] Embodiment 1. A composition comprising the antibiotic fosfomycin as an active ingredient for reducing or eliminating infection or colonization of colorectal cancer tumors by Fusobacteria and bacterial biofilms associated with colorectal cancer tumors, the composition being administered locally into the intestinal lumen.
[0057] 2. A composition comprising fosfomycin as an active ingredient for reducing or inhibiting the growth or metastasis of colorectal cancer in mammals or humans caused by Fusobacterial infection or colonization of cancer cells, the composition being administered locally into the intestinal lumen.
[0058] 3. A composition comprising fosfomycin as an active ingredient for sensitizing colorectal cancer cells in a mammal or human to chemotherapy or radiotherapy, the composition being administered locally into the intestinal lumen.
[0059] 4. A composition for use according to embodiments 1 to 3, further comprising one or more additional antibacterial or antibiotic agents as active ingredients.
[0060] 5. A composition for use according to embodiment 4, wherein the one or more additional antibacterial or antibiotic agents are selected from the list comprising metronidazole, or a carbapenem, such as ertapenem or meropenem or imipenem.
[0061] 6. A composition for use according to embodiment 4 or 5, in which the active ingredient fosfomycin is in the form of fosfomycin trometamol or fosfomycin disodium.
[0062] 7. A composition for use according to embodiments 4 to 6, wherein the active ingredient is formulated as a dry powder or granules that are dissolved in an aqueous medium before being delivered into the intestinal lumen.
[0063] 8. A composition for use according to embodiment 7, wherein said topical administration is a retention enema or a large volume enema.
[0064] 9. A composition for use according to embodiment 7 or 8, wherein said local administration is at the level of a tumor or biofilm via a colonoscope.
[0065] 10. A composition for use according to embodiment 7, wherein the dry powder or granules, and / or the aqueous medium for dissolution, contains one or more substances selected from the list: dimethyl sulfoxide, glycofurol, polyoxyethylene lauryl ether, sodium taurocholate, and sodium caprate.
[0066] 11. A composition for use according to any of the previous embodiments, wherein the composition is administered during neoadjuvant radiotherapy or chemotherapy, e.g., with bevacizumab and / or a cytotoxic agent.
[0067] 12. A composition for use according to any one of the previous embodiments, wherein the composition is administered in combination with systemic administration of an antibiotic to reduce or eliminate Fusobacteria or other viable microorganisms from tumor cells or metastases from tumors away from the intestinal wall.
[0068] 13. A method for reducing or eliminating infection or colonization of colorectal cancer tumors by Fusobacteria, including Fusobacterium nucleatum, and bacterial biofilms associated with such tumors in colorectal cancer patients, comprising locally administering into the intestinal lumen a composition comprising fosfomycin as an active ingredient.
[0069] 14. A method for inhibiting the growth or metastasis of colorectal cancer in a mammal or human caused by Fusobacterium infection or colonization of cancer cells, comprising locally administering into the intestinal lumen a composition comprising fosfomycin.
[0070] 15. A method for sensitizing colorectal cancer cells in a mammal or human to chemotherapy or radiation therapy, the method comprising locally administering into the intestinal lumen a composition comprising fosfomycin.
[0071] 16. The method according to any of embodiments 13 to 15, wherein the composition further comprises one or more additional antibacterial or antibiotic agents as active ingredients.
[0072] 17. The method according to embodiment 16, wherein the one or more additional antibacterial or antibiotic agents are selected from the list comprising metronidazole, or a carbapenem, such as ertapenem or meropenem or imipenem.
[0073] 18. The method according to embodiment 16 or 17, wherein the active ingredient fosfomycin is in the form of fosfomycin trometamol or fosfomycin disodium.
[0074] 19. The method according to embodiments 13 to 18, wherein the active ingredient is formulated as a dry powder or granules that are dissolved in an aqueous medium before being delivered into the intestinal lumen.
[0075] 20. The method according to embodiments 13 to 19, wherein said local administration is as a retention enema or a large volume enema.
[0076] 21. The method according to embodiment 20, wherein said local administration is at the level of a tumor or biofilm via a colonoscope.
[0077] 22. The method according to embodiment 21, wherein the dry powder or granules, and / or the aqueous medium for dissolution, contain one or more additional substances selected from the list: dimethyl sulfoxide, glycofurol, polyoxyethylene lauryl ether, sodium taurocholate, and sodium caprate.
[0078] 23. A method according to any of the previous embodiments, wherein the composition is administered simultaneously with neoadjuvant radiotherapy or chemotherapy, for example with bevacizumab and / or a cytotoxic drug.
[0079] 24. A method according to any of the previous embodiments, wherein the composition is administered in combination with systemic administration of antibiotics to reduce or eliminate Fusobacteria or other viable microorganisms from tumor cells or metastasis away from the intestinal wall. [References] TIFF2024169669000001.tif212169TIFF2024169669000002.tif226169TIFF2024169669000003.tif157169
Claims
1. A composition comprising fosfomycin as an active ingredient for use in reducing or eliminating infection or colonization of colorectal cancer tumors by fusobacteria, including Fusobacterium nucleatum, and the bacterial biofilms associated with such tumors, said composition being administered locally into the intestinal lumen.
2. The composition for use according to claim 1, wherein the composition further comprises one or more additional antibacterial or antibiotic agents as active ingredients.
3. 3. The composition for use according to claim 2, wherein the one or more additional antibacterial or antibiotic agents are selected from the list comprising metronidazole, or a carbapenem, such as ertapenem or meropenem or imipenem.
4. 4. A composition for use according to any one of claims 1 to 3, wherein the active ingredient fosfomycin is in the form of fosfomycin trometamol.
5. 4. The composition for use according to any one of claims 1 to 3, wherein the active ingredient fosfomycin is in the form of fosfomycin disodium.
6. 6. A composition for use according to any one of claims 1 to 5, wherein the active ingredient is formulated as a dry powder or granules that are dissolved in an aqueous medium prior to delivery into the intestinal lumen.
7. 7. The composition for use according to claim 6, wherein the topical administration is a retention enema or a large volume enema.
8. 7. The composition for use according to claim 6, wherein said local administration is at the level of a tumor or a bacterial biofilm via a colonoscope.
9. 7. The composition for use according to claim 6, wherein the dry powder or granules and / or the aqueous medium for dissolution contain one or more additional substances selected from the list: dimethyl sulfoxide, glycofurol, polyoxyethylene lauryl ether, sodium taurocholate, and sodium caprate.
10. 10. The composition for use according to any one of claims 1 to 9, wherein the composition is administered during neoadjuvant radiotherapy or chemotherapy, for example with bevacizumab and / or cytotoxic drugs.
11. A composition for use according to any one of claims 1 to 10, wherein the composition is administered in combination with systemic administration of an antibiotic to reduce or eliminate Fusobacteria or other viable microorganisms from tumor cells or metastases away from the intestinal wall.
Citation Information
Patent Citations
Compositions for eliminating bacterial promoters of colorectal cancer by intraluminal application - Patent Application 20070229633
JP7562413B2
Bacterial etiology of colorectal cancer
US20140107092A1
Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
US20170196937A1
Biofilm formation to define risk for colon cancer
WO2015038731A1
Treatment of cancer by manipulation of commensal microflora
WO2016196605A1
